Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory …
T Akamine, K Takada, G Toyokawa, F Kinoshita… - Surgical oncology, 2018 - Elsevier
Abstract Objectives Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1)
inhibitors have been approved as a standard therapy for metastatic non-small cell lung
cancer (NSCLC). Although PD-L1 expression serves as a predictive biomarker for the
efficacy of immunotherapy, there are no established biomarkers to predict the expression of
PD-L1. The inflammatory markers C-reactive protein (CRP) and neutrophil-lymphocyte ratio
(NLR) were recently shown to predict the efficacy of nivolumab for NSCLC patients …
inhibitors have been approved as a standard therapy for metastatic non-small cell lung
cancer (NSCLC). Although PD-L1 expression serves as a predictive biomarker for the
efficacy of immunotherapy, there are no established biomarkers to predict the expression of
PD-L1. The inflammatory markers C-reactive protein (CRP) and neutrophil-lymphocyte ratio
(NLR) were recently shown to predict the efficacy of nivolumab for NSCLC patients …
以上显示的是最相近的搜索结果。 查看全部搜索结果